Cargando…

Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: A preliminary study

CONTEXT: Peripheral anterior synechiae (PAS; synechiae anterior to functional trabecular meshwork) formation in primary angle-closure glaucoma (PACG) hampers access to uveoscleral outflow. Thus, the role of bimatoprost in such patients with 360° synechiae was evaluated. AIMS: To assess efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vyas, Prateep, Naik, Uday, Gangaiah, Jayasheel B
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032236/ https://www.ncbi.nlm.nih.gov/pubmed/21157066 http://dx.doi.org/10.4103/0301-4738.73708

Ejemplares similares

Cyclophotocoagulation in Neovascular Glaucoma with Near-Total Synechial Angle Closure
por: Wang, Jessie, et al.
Publicado: (2023)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study
por: Deshpande, Sarita S, et al.
Publicado: (2017)

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
por: Wang, Kaidi, et al.
Publicado: (2014)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis
por: Carruthers, Jean, et al.
Publicado: (2016)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat, Lutz E, et al.
Publicado: (2016)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Phacoemulsification with Intraocular Implantation of Lens, Endocyclophotocoagulation, and Endoscopic-Goniosynechialysis (PIECES): A Combined Technique for the Management of Extensive Synechial Primary Angle Closure Glaucoma
por: Alaghband, Pouya, et al.
Publicado: (2018)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review
por: Riahi, Ryan R, et al.
Publicado: (2018)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Floppy eyelid syndrome and ectropion improvement after 1 month of 0.03% Bimatoprost topical therapy
por: De Gregorio, Alessandra, et al.
Publicado: (2020)

A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
por: Natt, Navreet Kaur, et al.
Publicado: (2014)

First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost
por: Law, Simon K
Publicado: (2007)

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
por: Zaky, Mohamed S., et al.
Publicado: (2023)

Synéchies irido-cristallinniennes révélant une spondylarthrite ankylosante
por: Derrar, Rajae, et al.
Publicado: (2014)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma
por: Sihota, Ramanjit, et al.
Publicado: (2018)

Effect of Preoperative Factor on Intraocular Pressure after Phacoemulsification in Primary Open-angle Glaucoma and Primary Angle-closure Glaucoma
por: Kim, Woo-Jin, et al.
Publicado: (2019)

Intraocular pressure fluctuation after water drinking test in primary angle-closure glaucoma and primary open-angle glaucoma
por: Poon, Yi-Chieh, et al.
Publicado: (2016)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
por: Wirta, David, et al.
Publicado: (2011)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Inaccuracy of Intraocular Lens Power Prediction for Cataract Surgery in Angle-Closure Glaucoma
por: Kang, Sung Yong, et al.
Publicado: (2009)

Accuracy of Intraocular Lens Power Calculation Formulas in Primary Angle Closure Glaucoma
por: Joo, Jongsoo, et al.
Publicado: (2011)

Pseudophakic glaucoma and angle closure in a patient with an anterior chamber intraocular lens
por: Chan, Alison X., et al.
Publicado: (2020)

Dose–Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure
por: Lee, Susan S., et al.
Publicado: (2019)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ukroni4spfj9j8f62nq3tqrd0m